Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brian Zeithaml"'
Autor:
Mark A Titus, Brian Zeithaml, Boris Kantor, Xiangping Li, Karin Haack, Dominic T Moore, Elizabeth M Wilson, James L Mohler, Tal Kafri
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30192 (2012)
Prostate cancer (CaP) is the second leading cause of cancer death in American men. Androgen deprivation therapy is initially effective in CaP treatment, but CaP recurs despite castrate levels of circulating androgen. Continued expression of the andro
Externí odkaz:
https://doaj.org/article/acd202f4d611417ca97fd015a69978d3
Autor:
Hong Ma, Donald B. Kohn, Tal Kafri, Brian Zeithaml, Thipparat Suwanmanee, Yanmin Bi, Nate J. Fry, Peirong Hu
Publikováno v:
Gene therapy, vol 25, iss 7
Gene therapy
Gene therapy
Lentiviral vector mobilization following HIV-1 infection of vector-transduced cells poses biosafety risks to vector-treated patients and their communities. The self-inactivating (SIN) vector design has reduced, however, not abolished mobilization of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37369e6d0631f0caade3b4aba6173b5a
https://doi.org/10.1038/s41434-018-0039-2
https://doi.org/10.1038/s41434-018-0039-2
Autor:
Boris Kantor, Brian Zeithaml, Matthew Bayer, Adam S. Cockrell, Tal Kafri, Thomas J. McCown, Xiangping Li, Hong Ma
Publikováno v:
Molecular Therapy. 16(12):1968-1976
The feasibility of using nonintegrating lentiviral vectors has been demonstrated by recent studies showing their ability to maintain transgene expression both in vitro and in vivo. Furthermore, human immunodeficiency virus-1 (HIV-1) vectors packaged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771bfb8fbe223a82b2473204ac4d79bb
Autor:
James L. Mohler, Elizabeth M. Wilson, Brian Zeithaml, Dominic T. Moore, Xiangping Li, Mark Titus, Karin Haack, Tal Kafri, Boris Kantor
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30192 (2012)
PLoS ONE
PLoS ONE
Background Prostate cancer (CaP) is the second leading cause of cancer death in American men. Androgen deprivation therapy is initially effective in CaP treatment, but CaP recurs despite castrate levels of circulating androgen. Continued expression o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::402b3a65b6466d6f3d48d706630b5f6a
http://europepmc.org/articles/PMC3260230?pdf=render
http://europepmc.org/articles/PMC3260230?pdf=render
Autor:
Aravind Asokan, R. Jude Samulski, Chengwen Li, Brian Zeithaml, Tal Kafri, Matthew L. Hirsch, Hong Ma
A recent clinical trial has suggested that recombinant adeno-associated virus (rAAV) vector transduction in humans induces a cytotoxic T-lymphocyte (CTL) response against the AAV2 capsid. To directly address the ability of AAV capsid-specific CTLs to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957f2f8fffcfdfa59bd1e7613ed938a0
Autor:
Karin Haack, Angela Ponguta, Adam S. Cockrell, James L. Mohler, Elizabeth M. Wilson, Tal Kafri, Brian Zeithaml, Mark Titus
Publikováno v:
Molecular Therapy. 13:S365
An American dies from CaP every 17 minutes. Advanced prostate cancer almost always responds to androgen deprivation therapy but inevitably recurs as castration-resistant prostate cancer. Recent evidence suggests that the growth of most cases of castr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::172e135a05d32f16f91687ef291319b0
https://doi.org/10.1016/j.ymthe.2006.08.1037
https://doi.org/10.1016/j.ymthe.2006.08.1037